Literature DB >> 25220733

The origin and function of tumor-associated macrophages.

Yang Liu, Xuetao Cao.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25220733      PMCID： PMC4654376          DOI： 10.1038/cmi.2014.83

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  16 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Macrophage diversity enhances tumor progression and metastasis.

Authors:  Bin-Zhi Qian; Jeffrey W Pollard
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

3.  Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses.

Authors:  Yao-Chun Wang; Fei He; Fan Feng; Xiao-Wei Liu; Guang-Ying Dong; Hong-Yan Qin; Xing-Bin Hu; Min-Hua Zheng; Liang Liang; Lei Feng; Ying-Min Liang; Hua Han
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

4.  Apoptotic cell administration enhances pancreatic islet engraftment by induction of regulatory T cells and tolerogenic dendritic cells.

Authors:  Cong Wu; Yi Zhang; Yingming Jiang; Quanxing Wang; Yao Long; Chunmei Wang; Xuetao Cao; Guoyou Chen
Journal:  Cell Mol Immunol       Date:  2013-07-22       Impact factor: 11.530

Review 5.  Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease.

Authors:  Steven J Van Dyken; Richard M Locksley
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

Review 6.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

Review 7.  Macrophage biology in development, homeostasis and disease.

Authors:  Thomas A Wynn; Ajay Chawla; Jeffrey W Pollard
Journal:  Nature       Date:  2013-04-25       Impact factor: 49.962

8.  Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.

Authors:  Yanmei Han; Zhubo Chen; Yuan Yang; Zhengping Jiang; Yan Gu; Yangfang Liu; Chuan Lin; Zeya Pan; Yizhi Yu; Minghong Jiang; Weiping Zhou; Xuetao Cao
Journal:  Hepatology       Date:  2013-12-23       Impact factor: 17.425

9.  Notch signaling regulates expression of Mcl-1 and apoptosis in PPD-treated macrophages.

Authors:  Tanapat Palaga; Siriluk Ratanabunyong; Thitiporn Pattarakankul; Naunpun Sangphech; Wipawee Wongchana; Yukihiro Hadae; Patipark Kueanjinda
Journal:  Cell Mol Immunol       Date:  2013-07-22       Impact factor: 11.530

Review 10.  Tumor-associated macrophages: from mechanisms to therapy.

Authors:  Roy Noy; Jeffrey W Pollard
Journal:  Immunity       Date:  2014-07-17       Impact factor: 31.745
View more
  100 in total

1.  In Vitro Assay to Study Tumor-macrophage Interaction.

Authors:  Zhenyi An; William A Weiss
Journal:  J Vis Exp       Date:  2019-08-01       Impact factor: 1.355

Review 2.  Intratumoral dendritic cells in the anti-tumor immune response.

Authors:  Yang Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2015-01-19       Impact factor: 11.530

3.  Chemotherapeutic tumor microparticles combining low-dose irradiation reprogram tumor-promoting macrophages through a tumor-repopulating cell-curtailing pathway.

Authors:  Yanling Sun; Zu'an Zheng; Huafeng Zhang; Yuandong Yu; Jingwei Ma; Ke Tang; Pingwei Xu; Tiantian Ji; Xiaoyu Liang; Degao Chen; Xun Jin; Tianzhen Zhang; Zhixiong Long; Yuying Liu; Bo Huang
Journal:  Oncoimmunology       Date:  2017-03-31       Impact factor: 8.110

4.  Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy.

Authors:  Ashley Orillion; Nur P Damayanti; Li Shen; Remi Adelaiye-Ogala; Hayley Affronti; May Elbanna; Sreenivasulu Chintala; Michael Ciesielski; Luigi Fontana; Chinghai Kao; Bennett D Elzey; Timothy L Ratliff; David E Nelson; Dominic Smiraglia; Scott I Abrams; Roberto Pili
Journal:  Clin Cancer Res       Date:  2018-09-06       Impact factor: 12.531

5.  Peritumoral monocytes induce cancer cell autophagy to facilitate the progression of human hepatocellular carcinoma.

Authors:  Dong-Ping Chen; Wan-Ru Ning; Xue-Feng Li; Yuan Wei; Xiang-Ming Lao; Jun-Cheng Wang; Yan Wu; Limin Zheng
Journal:  Autophagy       Date:  2018-07-28       Impact factor: 16.016

6.  CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma.

Authors:  Guang-Tao Yu; Lin-Lin Bu; Yu-Yue Zhao; Liang Mao; Wei-Wei Deng; Tian-Fu Wu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 7.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

8.  A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.

Authors:  Ning Cheng; Rebekah Watkins-Schulz; Robert D Junkins; Clément N David; Brandon M Johnson; Stephanie A Montgomery; Kevin J Peine; David B Darr; Hong Yuan; Karen P McKinnon; Qi Liu; Lei Miao; Leaf Huang; Eric M Bachelder; Kristy M Ainslie; Jenny P-Y Ting
Journal:  JCI Insight       Date:  2018-11-15

9.  Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients.

Authors:  Jing Chen; Dan-Xue Zheng; Xing-Juan Yu; Hong-Wei Sun; Yi-Tuo Xu; Yao-Jun Zhang; Jing Xu
Journal:  Oncoimmunology       Date:  2019-08-15       Impact factor: 8.110

10.  Regulation of the IL-10-driven macrophage phenotype under incoherent stimuli.

Authors:  Yishan Chuang; Michelle E Hung; Brianne K Cangelose; Joshua N Leonard
Journal:  Innate Immun       Date:  2016-09-26       Impact factor: 2.680
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.